Inflammation in background cirrhosis evokes malignant progression in HCC development from HCV-associated liver cirrhosis

Scandinavian Journal of Gastroenterology

Volumn 48, Issue 6, 2013, Pages 729-735

  Tarao, Kazuo ^a   Ohkawa, Shinichi ^b   Miyagi, Yohei ^b   Morinaga, Soichiro ^b   Ohshige, Kenji ^c   Yamamoto, Naoto ^b   Ueno, Makoto ^b   Kobayashi, Satoshi ^b   Kameda, Ryo ^b   Tamai, Setsuo ^b   Nakamura, Yoshiyasu ^b   Miyakawa, Kaoru ^d   Kameda, Yoichi ^b   Okudaira, Masahiko ^e  

^a Tarao's Gastroenterological Clinic   (Japan)

^b KANAGAWA CANCER CENTER   (Japan)

^c YOKOHAMA NATIONAL UNIVERSITY   (Japan)

^d KANSAI UNIVERSITY OF WELFARE SCIENCES   (Japan)

^e KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatitis C virus associated liver cirrhosis; Hepatocellular carcinoma; Inflammation; Promotion; Stepwise promotion

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER SURGERY; CELL DEGENERATION; DISEASE ASSOCIATION; FEMALE; HEPATITIS; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER NECROSIS; LIVER NODULE; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

AGED; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HEPACIVIRUS; HEPATITIS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING;

EID: 84878428622     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2013.782064     Document Type: Article

References (44)

1. Poon TC, Wang N, Lai PB, Rattray M, Johnson PJ, Sung JJ. A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. Gastroenterology 2006;131:1262-70.
2. Kumada T, Toyoda H, Tada T, Sone Y, Fujimori M, Ogawa S, et al. Evolution of hypointence hepatocellular nodules observed only in the hepatobiliary phase using Gd-EOB-DTPA enhanced magnetic resonance imaging. Am J Roent 2011;197:58-63.
3. Kojiro M. Pathology of early hepatocellular carcinoma-Progression from early to advanced-. Hepat Gastroent 1998;45:1203-5.
4. Sugihara S, Nakashima O, Kojiro M, Majima Y, Tanaka M, Tanikawa K, et al. The morphologic transition in hepatocellular carcinoma-a comparison of the individual histological features disclosed by ultrasound-guided fine-needle biopsy with at autopsy. Cancer 1992;70:1488-92.
5. Ikeda K, Saitho S, Koida I, Arase Y, Tsubota A, Chayama K, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
6. Vasiliev JM, Moizhess TG. Tumorigenicity of sarcoma cells is enhanced by the local environment of implanted foreign body. Int J Cancer 1982;30:525-9.
7. Hamada J, Takeichi N, Okuda F, Ren J, Li X, Hosokawa M, et al. Progression of weakly malignant clone cells derived from rat mammary carcinoma by host cells reactive to plastic plates. Jpn J Cancer Res 1992;83:483-90.
8. Rincon M, James T, Bunn J. The role of post surgical inflammation in tumor progression in breast cancer [abstract number 392]. AACR Annual Meeting, 2012.
9. Deng J, Fujimoto J, Ye XF, Men TY, Van Peit CS, Chen YL, et al. Knockout of the tumor suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis. Cancer Prev Res (Phila) 2010;3:424-37.
10. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009;462: 104-7.
11. Muto M. Inflammation-induced tumor progression and its prevention. Exp Med 2011;29:139-44; in Japanese.
12. Okuda Y, Sawai H, Tanaka M, Manabe T. The role of inflammatory cytokine, IL-1 in the development of invasive pancreatic cancer. Jap J Gastroent Surg 2004;37:1331; in Japanese.
13. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
14. Knodell RG, Ishak KG, Black WC, Chen TS, Craig CR, Kaplowits N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1: 431-5.
15. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumors of the digestive system. Lyon: IARC press; 2010. pp 211-12.
16. Karin M, Cao Y, Greten FR, Li Z-W. NF-kB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2: 301-10.
17. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281:1680-3.
18. Wang W, Abbruzzese JL, Evans DP, Chiao PJ. Overexpression of urokinase-type plasmionogen activator in pancreatic adenocarcinoma is upregulated by constitutively activated RelA. Oncogene 1999;18:4554-63.
19. Ikebe T, Takeuchi H, Jimi E, Beppu M, Shinohara M. Involvement of proteasome in migration and matrix metalloproteinase-9 production of oral squamous cell carcinoma. Int. J. Cancer 1998;77:578-87.
20. Kobayashi K, Matsumoto S, Morishima T, Kawabe T, Okamoto T. Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking Eselectin expression. Cancer Res 2000;60:3978-84.
21. Kim IY, Stactman TC. Inhibition of NF-kB DNA binding and nitric oxide induction in human T cell and lung adenocarcinoma cells. Proc Natl Acad Sci USA 1997;94:12904-7.
22. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereic C, Strauss M. Nf-kB function in growth control: regulation of cyclin D1 expression and G0/G1-to S-phase transition. Mol Cell Biol 1999;19:2690-8.
23. Sasaki N, Morisaki T, Hashizume K, Yao T, Tsuneyoshi M, Noshiro H, et al. Nuclear factor-kB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res 2001;7:4136-42.
24. Barnes PJ, Karin M. NF-kB: a pivotal transcription factor in chronic inflammatory disease. N Engl J Med 1997;336: 1066-71.
25. Carbone C, Melsi D. NF-Kappa B as a target for pancreatic cancer therapy. Expert Opin Ther Targets 2012;16:51-60.
26. Pan H, Fu K, Huang W. Molecular mechanism of liver cancer. Anti-Canc. Agent in Med Chem 2011;11:439-99.
27. Okuda K. Space occupying lesions. In Okuda K, editor. Hepatobiliary diseases. Philadelphia: Blakwell Science; 2000. pp 395.
28. Tarao K, Rino Y, Ohkawa S, Shimizu A, Tamai S, Miyakawa K, et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 1999;86:589-95.
29. Veldt BJ, Hansen BE, Ikeda K, Verhey E, Suzuki H, Schalm SW. Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with nonresponse or relapse to interferon. Scand J Gastroenterol 2006;41:1087-94.
30. Miyakawa K, Tarao K, Ohshige K, Morinaga S, Ohkawa S, Okamoto N, et al. High serum alanine aminotransferase levels for the first three successive years can predict very high incidence of hepatocellular carcinoma in patients with Child Stage A HCV-associated liver cirrhosis. Scand J Gastroenterol 2009;44:1340-8.
31. Tarao K, Ohkawa S, Shimizu A, Harada M, Nakamura Y, Okamoto N, et al. DNA synthesis activities of hepatocytes from noncancerous cirrhotic tissue and of hepatocellular carcinoma (HCC) cells from cancerous tissue can predict the survival of hepatectomized patients with HCC. Cancer 1993;71:3859-63.
32. Suzuki F, Ikeda K, Toyota J, Karino Y, Ohmura T, Chayama K, et al. Dual oral therapy with the NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1b-infected null responders or patients ineligible/intoleranto to peginterferon/ribavirin [Abstract 2344]. The International Liver Congress 2012: 47th Annual Meeting of the European Association for the Study of the Liver Barcelona, Spain, April 18-22 2012.
33. Shiffman ML, Hoffmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117:1164-72.
34. Arase Y, Ikeda K, Tsubota A, Suzuki F, Suzuki Y, Saitoh S, et al. Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection. Intervilorogy 2004; 47:355-61.
35. Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, et al. Interferon-induced prolonged biochemical responce reduces hepatocarcinogenesis in hepatitis C virus infection. J Med Virol 2007;79:1485-90.
36. Nomura H, Kashiwagi Y, Hirano R, Tanimoto H, Tsutsumi N, Higashi M, et al. Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetorotein: a pilot study. Hepatology Res 2007;37:490-7.
37. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011; 140:840-9.
38. Bellentani S, Podda M, Tiribelli C, Callea F, Marazzi M, Sodde M, et al. Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. J Hepatol 1993;19:459-64.
39. Omata M, Yoshida H, Toyota J, Tomita E, Nishiguchi S, Hayashi N, et al. A large-scale, multicenter, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 2007;56:1747-53.
40. Suzuki H, Ohta Y, Takino T, Fujisawa K, Hirayama C. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis-double blind trial. Asian Med J 1983;26: 423-8.
41. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997;79:1494-500.
42. Hirayama C, Okumura M, Tanikawa K, Yano M, Mizuta M, Ogawa N. A multicenter randomized control clinical trial of Sho-saiko-to in chronic active hepatitis. Gastroenterol Jpn 1989;24:715-19.
43. Oka H, Yamamoto S, Kuroki T, Harihara S, Marumo T, Kim SR, et al. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 1995;76:743-9.
44. Tarao K, Sakamoto Y, Ueno M, Miyakawa K, Ohkawa S. Juzentaihoto (TJ48) may be an important and effective antiinflammatory agent for intractable cases of patients with HCV-associated chronic liver diseases. Kampo Med 2010; 61:1-8.